Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04113668 · ClinicalTrials.gov registry record · Phase 1
The Effects Diflunisal on the Levels of BMS-986165 in Healthy Participants
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT04113668 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 48 participants.
The verdict
NCT04113668, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
BMS-986165 Is broken down by the body through multiple pathways. This study Investigates the effect of blocking one pathway in the drug levels of BMS-986165 in health subjects.
Interventions
- DRUG BMS-986165
- DRUG diflunisal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2019-10-01 |
| Est. Completion | 2019-11-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04113668
The ClinicalTrials.gov registry entry for NCT04113668 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which BMS-986165 is the first listed.
NCT04113668 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04113668 about?
NCT04113668 is a clinical study titled "The Effects Diflunisal on the Levels of BMS-986165 in Healthy Participants". BMS-986165 Is broken down by the body through multiple pathways. This study Investigates the effect of blocking one pathway in the drug levels of BMS-986165 in health subjects.
What is the current status of trial NCT04113668?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2019-10-01. Estimated completion is 2019-11-25.
What interventions are being tested in trial NCT04113668?
The interventions under investigation include: BMS-986165 (DRUG), diflunisal (DRUG).
Who is sponsoring clinical trial NCT04113668?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.